Published in Cancer Weekly, April 17th, 2006
Intravenous (IV) treatment with bisphosphonates such as pamidronate (Novartis's Aredia) and zoledronic acid (Novartis's Zometa), in conjunction with standard chemotherapy, has become the standard of care for patients with bone lesions due to multiple myeloma and for patients with solid tumors who have bone metastases. These agents are used to reduce the incidence of bone-metastasis-related exacerbations such as bone pain, fractures, and spinal cord compression.
A major new potential market segment for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.